Chr del(9)(p21.3)

News alerts, weekly reports and conference planners

Chr del(9)(p21.3)	Renal Cell Carcinoma	Chr del(9)(p21.3)	Renal Cell Carcinoma	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
Chr del(9)(p21.3)	Lung Non-Squamous Non-Small Cell Cancer	Chr del(9)(p21.3)	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
Chr del(9)(p21.3)	Solid Tumor	Chr del(9)(p21.3)	Solid Tumor	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
Chr del(9)(p21.3)	Solid Tumor	Chr del(9)(p21.3)	Solid Tumor	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3

Associations